Handelsavisen
prelaunch
Companies Basic Materials BIOX.O
BI
BIOX.O NASDAQ Chemicals

Bioceres Crop Solutions Corp

$0,37
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
23,6M USD
P/E
EV / Rev
0,9x
Div yield
Op margin
15,7 %
ROE
2,9 %
Net margin
11,0 %
Debt / equity
0,81
Beta
52w range
Volume
3
Day range
Prev close
$0,42
Open
Next earnings
Ex-dividend
TR 1Y
About

Bioceres Crop Solutions Corp develops and commercializes biological crop protection and enhancement solutions, primarily targeting the agricultural sector.

Business. Bioceres Crop Solutions Corp (BIOX.O) is an agricultural chemicals company operating within the Basic Materials sector. The firm is headquartered in Argentina and primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.

Classification99 %
SectorBasic Materials
Industry groupChemicals
Generated · model-assisted
Sell-side consensus
HOLD1 analysts
0 buy1 hold0 sell
Avg 12m price target

Analyst recommendations

1 analysts · consensus Hold
Buy0
Hold1
Sell0
12-month price target
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Hold
1 analysts · indicative
Ownership
PNC Investments LLC
largest disclosed fund holder
Profitability
2,9 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning BIOX.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials · THIS SECTOR+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to BIOX.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Bioceres Crop Solutions Corp (BIOX.O) is an agricultural chemicals company operating within the Basic Materials sector. The firm is headquartered in Argentina and primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.

    Classification99 %
    SectorBasic Materials
    Industry groupChemicals
    AI synthesis
    GENERATED

    Bioceres operates with a market cap of $28.7 million and a price-to-book ratio of 0.09, indicating a significant discount to its book value. The company's liquidity position is characterized by $16.4 million in cash and equivalents, but its long-term debt of $255.1 million creates a debt-to-equity ratio of 0.81, suggesting moderate leverage. The current ratio of 1.22 indicates the company can cover its short-term liabilities with its current assets, but the margin is narrow.

    Profitability metrics show a return on equity of 2.95% and a return on assets of 1.11%, both below the industry median for Agricultural Chemicals. The company's net income of $9.3 million on $84 million in revenue yields a net margin of 11%, which is in line with the industry median but not exceptional. Gross profit of $42.7 million on $84 million in revenue results in a gross margin of 50.8%, which is strong and suggests efficient cost management.

    Geographically, Bioceres' revenue is concentrated in a few key markets, with the Americas accounting for the majority of its sales. The company has not disclosed specific segment breakdowns, but its exposure to the agricultural sector makes it sensitive to commodity price fluctuations and regulatory changes in agrochemicals. The company's capital expenditures of -$16.7 million suggest a reduction in investment in physical assets, which may reflect a strategic shift or financial constraints.

    Looking ahead, the company is expected to report a net loss of $0.16 per share in the current fiscal year, a significant improvement from the $0.82 loss in the previous year. However, the mean analyst recommendation of 3.00 (Hold) suggests limited upside potential in the near term. The company's free cash flow of $8.7 million indicates some capacity to fund operations or reduce debt, but the negative net cash position after subtracting total debt raises concerns about long-term liquidity.

    The risk assessment highlights a medium liquidity risk due to the company's negative net cash position after subtracting total debt. The dilution risk is rated as low, with no significant dilution expected in the near term. The company's capital structure and financial flexibility are constrained by its high debt load, which could limit its ability to invest in growth opportunities.

    Recent filings and transcripts indicate that the company is focused on expanding its product portfolio and entering new markets. However, the lack of strong buy recommendations from analysts and the current market price of $0.4494 suggest that investor sentiment remains cautious. The company's recent performance and strategic direction will be critical in determining its future trajectory.

    Key takeaways
    • Bioceres trades at a significant discount to book value, with a price-to-book ratio of 0.09.
    • The company's gross margin of 50.8% is strong, but its return on equity of 2.95% is below the industry median.
    • The company's liquidity position is constrained by a negative net cash position after subtracting total debt.
    • Analysts have a neutral outlook, with a mean recommendation of 3.00 (Hold).
    • The company's free cash flow of $8.7 million provides some financial flexibility but is insufficient to cover its debt load.
    • The company's strategic focus on expanding its product portfolio and entering new markets may drive future growth.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 4

    Net margin of 11.0% ranks above the 75th percentile of the 139-company Agricultural Chemicals cohort benchmark.

    Revenue grew at a 12.7% compound annual growth rate over the four-year period ending in fiscal 2025.

    Cash conversion ratio of 1.99 is more than double the 0.9 cohort median, suggesting strong cash generation relative to earnings.

    Gross profit reached $129.9 million in fiscal 2025, maintaining a robust margin despite significant revenue contraction.

    BEAR CASE · 1

    The company carries a high credit risk flag, compounded by long-term debt increasing to $276.6 million in fiscal 2025.

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-03-13
    Q4 2025 · Quarter highlights
    Open report →

    Revenue $73.7M, −25,5% YoY; Operating income −47,6% YoY.

    Revenue$73.7M−25,5 % YoY
    Operating income$7.5M−47,6 % YoY
    Net income-$183.0M−127 618,3 % YoY
    Free cash flow-$1.2M−130,0 % YoY
    EPS
    Operating cash flow$31.8M+16 111,0 % YoY
    Financials
    Income statement
    Revenue$73.7M
    Gross profit$26.5M
    Operating income$7.5M
    Net income-$183.0M
    Margins
    Gross margin36.0%
    Operating margin10.2%
    Net margin-248.4%
    FCF margin-1.6%
    Balance sheet
    Total assets$560.4M
    Total liabilities$484.0M
    Total equity$76.4M
    Cash & equivalents$11.1M
    Long-term debt$239.5M
    Cash flow
    Operating cash flow$31.8M
    CapEx-$1.6M
    Free cash flow-$1.2M
    SBC
    P&L flow · revenue → net income
    Revenue $73.7MOperating costs $66.2MTax $190.6MNet income $183.0M
    Highlights
    • Revenue $73.7M, −25,5% YoY
    • Operating income −47,6% YoY
    • Net income −127 618,3% YoY
    • Free cash flow −130,0% YoY
    • Net margin -248.4%

    Valuation TTM

    Market price
    $0,37
    Market cap
    $28.7M
    Enterprise value
    $267.4M
    P/E
    Non-GAAP P/E
    EV / Revenue
    0.9x
    EV / Op income
    121.2x
    EV / OCF
    14.5x
    P / B
    0.1x
    P / Tangible book
    0.1x
    Tangible book
    $313.4M
    Net cash
    -$238.7M
    Current ratio
    1.2
    Debt / equity
    0.8
    ROA
    1.1%
    ROE
    2.9%
    Cash conversion
    199.0%
    CapEx / revenue
    -19.9%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Crop Nutrition
    low · business_description · 2026-07-04
    Crop Protection
    low · business_description · 2026-07-04
    Seeds & Traits
    low · business_description · 2026-07-04

    Market share

    INDUSTRYSEGMENTCOMPANYBasic MaterialsIndustryChemicals61,0B node revenueNTR 44,1%CTVA 28,5%ICL 11,7%FMC 5,7%SMG 5,6%LVROF 3,0%AVD 0,8%BIOX 0,6%
    Source: company disclosures · own-taxonomy revenue-covered setBIOX 0,6% · rank #8 of 9

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    Peer comparison7 peers · vs BIOX · multiples and returns
    NT
    NTR
    NUTRIEN LTD.
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    CT
    CTVA
    Corteva Inc
    $76,04
    51,2B USD
    P/E
    49,4x
    +46,3 vs self
    Div yield
    0,8 %
    vs self
    ROE
    4,5 %
    +1,5 vs self
    IC
    ICL
    ICL.TA
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    FM
    FMC
    Fmc Corp
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    SM
    SMG
    Scotts Miracle-gro Co
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    LV
    LVROF
    Lavoro Ltd
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    AV
    AVD
    American Vanguard Corp
    $2,46
    70,5M USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -2,2 %
    -5,1 vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -0,16
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    1
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-16 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate-0,16
    Revenueno estimateno estimate307,1M USD
    Operating incomeno estimateno estimate21,9M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy0
    Hold1
    Sell0
    Strong sell0
    Operating income · consensus21,9M USD
    EPS surprise
    −412,5 %
    reported vs consensus · miss
    Revenue surprise
    +9,2 %
    reported vs consensus · beat

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin15,7 %Above median
    Net Margin11,0 %Above P75
    ROE2,9 %Below median
    Capex / Rev-19,9 %Bottom quartile
    D/E0,81Below median
    Cash Conv1,99Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Earnings
      market_price / (net_income / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    Source documents
    • Bioceres Crop Solutions Corp Market data — financials · 2026-05-27
    • Bioceres Crop Solutions Corp Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Top holders

    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Invesco QQQ TrustFunds · as of 2026-03-310,00 %$0M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$0M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M

    Leadership

    • Federico TruccoChief Executive Officer, Executive Director

    Insider activity

    — missing data

    Short positioning

    1.1Mshares short+15.5% vs prior
    7.81days to cover
    68.9%short of daily vol
    63fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    BIOX.OCanonical
    NASDAQ · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-07-29 22:34 UTCEVENTHa Price Listing BIOX remains DEFICIENT (NASDAQ) — cure period. closed below $1.00 for 94 consecutive trading days (last close $0.42). cure deadline 2027-01-17 (172 days remaining).
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-01FILINGFORM 6-K →
    2026-05-12FILINGFORM 6-K →
    2026-03-17FILINGFORM 6-K →
    2026-03-17FILINGFORM 6-K →
    2026-03-13 17:25 UTCEARNINGSQuarterly results — Q4 2025 Revenue USD 73.7M · Net USD -183.0M
    2026-03-13FILING6-K filing →
    2026-01-20FILINGFORM 6-K →
    2026-01-09FILINGFORM 6-K →
    2025-12-31FILINGFORM 6-K →
    2025-12-22FILINGFORM 6-K →
    2025-11-26FILING6-K filing →
    2025-11-13FILINGFORM 6-K →
    2025-11-12 17:15 UTCEARNINGSQuarterly results — Q3 2025 Revenue USD 77.4M · Net USD -7.3M
    2025-11-12FILINGFORM 6-K →
    2025-09-09 06:00 UTCEARNINGSQuarterly results — Q2 2025 Revenue USD 74.4M · Net USD -47.9M
    2025-09-09 06:00 UTCEARNINGSAnnual results — FY 2025 Revenue USD 333.3M · Net USD -55.4M
    2025-05-21 07:01 UTCEARNINGSQuarterly results — Q1 2025 Revenue USD 59.6M · Net USD -1.3M
    2025-02-11 18:18 UTCEARNINGSQuarterly results — Q4 2024 Revenue USD 98.9M · Net USD 0.1M
    2024-11-11 19:27 UTCEARNINGSQuarterly results — Q3 2024 Revenue USD 92.6M · Net USD -6.4M
    2024-09-09 19:24 UTCEARNINGSQuarterly results — Q2 2024 Revenue USD 124.3M · Net USD -0.5M
    2024-09-09 19:24 UTCEARNINGSAnnual results — FY 2024 Revenue USD 464.8M · Net USD 4.3M
    2024-05-13 17:46 UTCEARNINGSQuarterly results — Q1 2024 Revenue USD 84.0M · Net USD 9.3M
    2023-09-11 16:02 UTCEARNINGSAnnual results — FY 2023 Revenue USD 415.1M · Net USD 18.8M
    2022-09-08 06:00 UTCEARNINGSAnnual results — FY 2022 Revenue USD 328.4M · Net USD -7.2M
    2021-09-09 06:00 UTCEARNINGSAnnual results — FY 2021 Revenue USD 206.7M · Net USD -6.9M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage